158 related articles for article (PubMed ID: 28774186)
1. Is immunotherapy a viable option in treating mesothelioma?
Dumoulin DW; Aerts JG; Cornelissen R
Future Oncol; 2017 Aug; 13(20):1747-1750. PubMed ID: 28774186
[No Abstract] [Full Text] [Related]
2. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
[TBL] [Abstract][Full Text] [Related]
3. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
5. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
[TBL] [Abstract][Full Text] [Related]
6. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
Front Immunol; 2018; 9():2034. PubMed ID: 30245692
[No Abstract] [Full Text] [Related]
7. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
Aerts JGJV; de Goeje PL; Cornelissen R; Kaijen-Lambers MEH; Bezemer K; van der Leest CH; Mahaweni NM; Kunert A; Eskens FALM; Waasdorp C; Braakman E; van der Holt B; Vulto AG; Hendriks RW; Hegmans JPJJ; Hoogsteden HC
Clin Cancer Res; 2018 Feb; 24(4):766-776. PubMed ID: 29233904
[No Abstract] [Full Text] [Related]
8. Anti-CTLA-4 therapy for malignant mesothelioma.
Guazzelli A; Bakker E; Krstic-Demonacos M; Lisanti MP; Sotgia F; Mutti L
Immunotherapy; 2017 Mar; 9(3):273-280. PubMed ID: 28231719
[TBL] [Abstract][Full Text] [Related]
9. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
Calabrò L; Ceresoli GL; D'Incecco A; Scherpereel A; Aerts J; Maio M
Cytokine Growth Factor Rev; 2017 Aug; 36():25-31. PubMed ID: 28736182
[TBL] [Abstract][Full Text] [Related]
11.
De La Maza L; Wu M; Wu L; Yun H; Zhao Y; Cattral M; McCart A; Cho BJ; de Perrot M
Clin Cancer Res; 2017 Sep; 23(18):5502-5513. PubMed ID: 28606922
[No Abstract] [Full Text] [Related]
12. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
Ceresoli GL; Bonomi M; Sauta MG
Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
[No Abstract] [Full Text] [Related]
13. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
Hegmans JP; Hemmes A; Aerts JG; Hoogsteden HC; Lambrecht BN
Am J Respir Crit Care Med; 2005 May; 171(10):1168-77. PubMed ID: 15764728
[TBL] [Abstract][Full Text] [Related]
15. Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
Cornelissen R; Hegmans JP; Maat AP; Kaijen-Lambers ME; Bezemer K; Hendriks RW; Hoogsteden HC; Aerts JG
Am J Respir Crit Care Med; 2016 May; 193(9):1023-31. PubMed ID: 26652184
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
[No Abstract] [Full Text] [Related]
17. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
Hegmans JP; Veltman JD; Lambers ME; de Vries IJ; Figdor CG; Hendriks RW; Hoogsteden HC; Lambrecht BN; Aerts JG
Am J Respir Crit Care Med; 2010 Jun; 181(12):1383-90. PubMed ID: 20167848
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
Ebstein F; Sapede C; Royer PJ; Marcq M; Ligeza-Poisson C; Barbieux I; Cellerin L; Dabouis G; Grégoire M
Am J Respir Crit Care Med; 2004 Jun; 169(12):1322-30. PubMed ID: 15070823
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
Yu G; Moudgil T; Cui Z; Mou Y; Wang L; Fox BA; Hu HM
J Immunother; 2017 Jun; 40(5):155-163. PubMed ID: 28368960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]